Last reviewed · How we verify
Adaptive autologous cell immunotherapy
At a glance
| Generic name | Adaptive autologous cell immunotherapy |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma (PHASE2)
- ImmunoBreast - A Phase Ib Study (PHASE1, PHASE2)
- ImmuniCell® in Patients With Advanced Cancers (PHASE2)
- Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma (NA)
- T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: